On November 10th, 2020, the Centers for Medicare and Medicaid services announced that Medicare beneficiaries can receive coverage of monoclonal antibodies to treat COVID-19 with no cost-sharing during the public health emergency. The V-BID principle of reducing financial barriers to essential clinical care has been a consistent theme in the federal government’s, states’ and private payers’ responses to the COVID-19 pandemic.